A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.
Cataldo PatrunoGabriella FabbrociniGiuseppe LaulettaValeria BoccalettiCristiana ColonnaRiccardo CavalliIria NeriMichela OrtoncelliDonatella SchenaLuca StingeniKatharina HanselVincenzo PiccoloVeronica Di BrizziConcetta PotenzaErsilia TolinoLuca BianchiSara MantiRocco De PasqualeVito Di LerniaLucia CaminitiElena GalliPaola CoppoAndrea ChiricozziClara De SimoneCristina GuerrieroFabrizio Giuseppe AmorusoEugenio ProvenzanoSalvatore LeonardiAmelia LicariGian Luigi MarsegliaAntonino PalermoSabrina Di PilloDaniele RussoViviana MoscheseVincenzo PatellaTiziana PedutoCaterina FerreliPaola ZangariFederica VeroneseSamantha Federica BertiMichaela GruberElena PezzoloStefania TermineRosanna SattaFederica DragoniMaria EspositoMaria Concetta FargnoliPaolo ChiodiniYlenia ValloneFrancesca di VicoVincenzo PiconeMaddalena NapolitanoPublished in: The Journal of dermatological treatment (2023)
Background: Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months to 11 years in randomized clinical trials. Aim: The aim of this real-life study was to determine the effectiveness in disease control and safety of dupilumab at W52 in moderate-to-severe AD children aged 6-11 years. Methods: All data were collected from 36 Italian dermatological or paediatric referral centres. Dupilumab was administered at label dosage with an induction dose of 300 mg on day 1 (D1), followed by 300 mg on D15 and 300 mg every 4 weeks (Q4W). Treatment effect was determined as overall disease severity, using EASI, P-NRS, S-NRS and c-DLQI at baseline, W16, W24, and W52. Ninety-six AD children diagnosed with moderate-to-severe AD and treated with dupilumab were enrolled. Results: Ninety-one (94.8%) patients completed the 52-week treatment period and were included in the study. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to weeks 16, 24 and 52. Conclusions: Our real-life data seem to confirm dupilumab effectiveness and safety in paediatric patients. Moreover, our experience highlighted that patients achieving clinical improvement at W16 preserved this condition over time.
Keyphrases
- atopic dermatitis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- young adults
- prognostic factors
- systematic review
- peritoneal dialysis
- randomized controlled trial
- machine learning
- clinical trial
- high intensity
- patient reported outcomes
- patient reported
- artificial intelligence
- preterm birth